Bio-Rad Laboratories (BIO) Scheduled to Post Quarterly Earnings on Tuesday

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) is scheduled to announce its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $2.04 per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.17. The company had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.31 earnings per share. On average, analysts expect Bio-Rad Laboratories to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Bio-Rad Laboratories Stock Down 2.7 %

Shares of NYSE:BIO traded down $7.36 during mid-day trading on Tuesday, reaching $269.75. 306,992 shares of the stock were exchanged, compared to its average volume of 203,622. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. The company has a market cap of $7.69 billion, a P/E ratio of -12.55 and a beta of 0.87. Bio-Rad Laboratories has a one year low of $261.59 and a one year high of $473.50. The stock's 50 day simple moving average is $323.67 and its 200-day simple moving average is $316.47.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BIO shares. Royal Bank of Canada decreased their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating for the company in a report on Friday, February 16th. Citigroup cut Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and reduced their price target for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. UBS Group increased their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a "buy" rating in a research report on Friday, February 16th. Finally, StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and a consensus target price of $468.00.

Insider Activity

In other news, EVP Michael Crowley sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company's stock, valued at $2,332,512. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 17.50% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.